Download Action Plan - Australian Packaging Covenant

Australian Packaging
Covenant
CSL Biotherapies
Action Plan
2011 – 2015

CONTENTS
EXECUTIVE SUMMARY .................................................................................................. 2
1. COMPANY PROFILE ................................................................................................ 3
1.1. BACKGROUND .............................................................................................................................................................. 3
1.2. ENVIRONMENT ............................................................................................................................................................ 3
1.3. BRAND OWNERSHIP .................................................................................................................................................... 4
1.4. PACKAGING MATERIALS AND FORMATS ................................................................................................................. 5
1.5. BUSINESS LOCATIONS ................................................................................................................................................. 6
2. PLAN MANAGEMENT ............................................................................................. 7
2.1. COVENANT CONTACT................................................................................................................................................. 7
2.2. AUSTRALIAN PACKAGING COVENANT TEAM ........................................................................................................ 7
2.3. IMPLEMENTATION PROCESS FOR SPG .................................................................................................................... 7
3. ACTION PLAN ........................................................................................................... 8
3.1. DESIGN .......................................................................................................................................................................... 8
3.2. RECYCLING ................................................................................................................................................................... 9
3.3. PRODUCT STEWARDSHIP .......................................................................................................................................... 10
3.4. ACTION PLAN ENDORSEMENT ............................................................................................................................... 11
1

Executive Summary
CSL Limited (CSL, ABN: 99 051 588 348) is a global, specialty biopharmaceutical company
that researches, develops, manufactures and markets products to treat and prevent serious
human medical conditions. With major facilities in Australia, Germany, Switzerland and the
U.S., CSL has over 10,000 employees working in more than 20 countries.
In Australia, CSL Biotherapies manufactures, markets and distributes plasma-derived
therapies, vaccines, immunohaemotology products and antivenoms. We also in-license,
market and distribute a range of pharmaceutical products.
Much of our packaging is selected based on the nature of the products which we develop,
manufacture and market to ensure we meet requirements with respect to product safety,
efficacy and transportability throughout the supply chain. We continue to be committed to
the Australian Packaging Covenant and continue to make financial instalments as Brand
Owner, in accordance with the Covenant guidelines.
The development of the 2011-2015 action plan has involved a review of actions from our
previous commitments under the National Packaging Covenant, and also the requirements
of the Australian Packaging Covenant with alignment to their Goals, Outcomes and KPIs.
Our action plan also outlines the key activities which CSL will undertake to assess and
implement, as feasible, activities and processes that support the integration of the Sustainable
Packaging Guidelines into our packaging review processes.
Formalisation of processes in line with the Sustainable Packaging Guidelines will ensure we
are able to meet the expectations of the Covenant, whilst demonstrating commitment to
implementation of key initiatives where they are feasible from a customer, financial, technical
and environmental perspective.
Baseline data has not been included in our 2011-2015 action plan, however, data can be
obtained from CSL’s previous National Packaging Covenant Annual Reports, accessible on
the Covenant website.
The 2011-2015 action plan outlines the key actions, accountabilities and indicators for the
period of March 2011 – June 2015.
2

1. Company Profile
1.1. Background
We are Australia’s chosen national plasma fractionator and, under contract to
Australia’s National Blood Authority, manufacture a complete range of life saving
plasma-derived therapies for the treatment of the Australian community. The
range of plasma-derived therapies we manufacture for Australia is the largest
manufactured in a single facility globally. It is also the only range in which every
product is manufactured using processes that include at least two dedicated and
complementary pathogen reduction steps. We are also the chosen national
plasma fractionator of New Zealand, Hong Kong, Malaysia, Singapore and
Taiwan.
We also manufacture a range of immunohaematology products (diagnostic
reagents) that are supplied to Australian laboratories to enhance the safety of
blood transfusions for patients in Australia.
We also operate one of the world’s largest influenza vaccine manufacturing
facilities and supply seasonal influenza vaccines to Australia and global markets.
Working closely with public health authorities and the Australian Department of
Health & Ageing we have used our influenza vaccine technology to develop and
license a safe and effective pandemic influenza vaccine providing biosecurity to
Australia’s population in the event of an influenza pandemic such as the 2009
swine flu. We are Australia’s first line of defence against pandemic influenza.
1.2. Environment
Our commitment to the environment is set by the Board and articulated in our
Code of Responsible Business Practice. Executive management teams and the
Audit and Risk Management Committee of the CSL Board monitor
environmental performance.
Business unit leaders ensure all sites work within CSL’s global environmental
framework. Our Global Environment Policy provides further guidance to
management and staff. HSE staff at each site collaborates with functional groups
to manage and improve environmental performance relative to local impacts.
We continue to report on various regulatory and voluntary programs which are
also supported by internal targets which have been established to minimise the
environmental impacts of our operations. Additional information on our
environmental performance can be found on our website www.csl.com.au.
3

1.3. Brand Ownership
As part of our 2009/10 submission under the National Packaging Covenant
(NPC), a review of in-licensed products was undertaken to improve our reporting
capabilities.
The work involved establishing a systematic methodology to determine
applicability for inclusion in our assessment of products applicable under the
NPC. In our 2009/10 NPC annual report, it was noted that a review of our
product suite would be required to ascertain products that are applicable to the
Australian Packaging Covenant (APC) would be conducted.
This activity has been included in our 2011-2015 action plan in Section 3. The
review will provide greater guidance on our focus areas for the APC.
Major plasma-derived therapies manufactured by CSL Biotherapies
Haemophilia and Other Coagulation Disorders BIOSTATE ®
MonoFIX ® -VF
PROTHROMBINEX ® -VF
Critical Care Conditions ALBUMEX ®
Immune Disorders and Immune Therapy
THROMBOTROL ® -VF
INTRAGRAM ® P
Normal Immunoglobulin - VF
Rh(D) Immunoglobulin-VF
CMV Immunoglobulin-VF
Hepatitis B Immunoglobulin-VF
Zoster Immunoglobulin-VF
Tetanus Immunoglobulin-VF
Major vaccines and pharmaceutical products manufactured by CSL Biotherapies
Vaccines Fluvax ®
Panvax ®
Q-Vax ®
Antivenoms
Black Snake antivenom
Box Jellyfish antivenom
Brown Snake antivenom
Death Adder antivenom
Funnel Web Spider antivenom
Polyvalent Snake antivenom
Red Back Spider antivenom
Sea Snake antivenom
Stonefish antivenom
Taipan antivenom
Tiger Snake antivenom
Table 1.3-1 Major products manufactured by CSL Biotherapies.
Other major vaccines and pharmaceutical products marketed / in-licensed by
CSL Biotherapies in Australia can be found on our website. www.csl.com.au
4

1.4. Packaging Materials and Formats
Packaging plays an integral part in achieving and maintaining the integrity of our
products as they are transported throughout the supply chain.
The very nature of our products makes modifications to packaging with direct
product contact challenging as significant limitations exist in the selection of
materials as product safety and product efficacy are of paramount importance.
Materials used for secondary and tertiary packaging are selected to ensure
temperature stability, transportability and storage which also ensure product
integrity throughout the supply chain. Secondary and tertiary packaging and the
treatment of recyclable packaging waste is an area which undergoes continuous
improvement and actions have been included in our 2011-15 action plan in
Section 3 for further enhancement.
Table 1.4-1 lists our major packaging materials and their formats.
Materials
Aluminium
Composites
Plastics
Paper
Cardboard
Glass
Formats
Caps
Blister Packs
Flow wrap / Stoppers / Syringes
Leaflets / Carton Inserts
Cartons / Shippers
Bottles / Vials
Other*
Eskies / Needles / Packaging Tape / Pallets
Table 1.4-1 Major Packaging Materials and Formats.
As part of our 2009/10 report under the NPC, it was estimated that
approximately 281.4 tonnes of packaging was used for products manufactured
and in-licensed by CSL Biotherapies, compared to 253.7 tonnes for 2008/09. 1
Glass and cardboard
remain the predominant
packaging materials for
both CSL manufactured
and in-licensed products.
Glass is used vials and
bottles, whilst cardboard
is used to contain,
protect and transport
product.
Figure 1.4-1 Packaging quantities trend
An outline of the implementation process of the Sustainable Packaging
Guidelines (SPG) is detailed in Section 2.3.
1 2009/10 includes packaging from in-licensed products.
5

1.5. Business Locations
CSL Limited
ABN 99 051 588 348
Registered Head Office
45 Poplar Road
Parkville
Victoria 3052
Australia
Telephone: + 61 3 9389 1911
Facsimile: + 61 3 9389 1434
CSL has major manufacturing facilities in the following locations:
CSL Limited, Biotherapies Division
ABN 99 051 588 348
Broadmeadows
Parkville
189 Camp Road 45 Poplar Road
Broadmeadows
Parkville
Victoria 3047 Victoria 3052
Australia
Australia
Telephone: + 61 3 9246 5200 Telephone: + 61 3 9389 1911
Facsimile: + 61 3 9246 5299 Facsimile: + 61 3 9389 1434
We also have distribution warehouses in Western Australia, South Australia, New
South Wales and Queensland. Additional details can be found on our website
www.csl.com.au
6

2. Plan Management
2.1. Covenant Contact
For further information regarding our 2011-15 Action Plan contact:
Margaret Shilling
National Health, Safety & Environment Manager
Tel: (03) 9389 1773
Fax: (03) 9389 1180
2.2. Australian Packaging Covenant Team
The Health, Safety & Environment (HS&E) Department has broad responsibility
of reporting to the Australian Packaging covenant. The HS&E Department is
also the primary contact for the APC.
Execution of the 2011-2015 action plan will be achieved through cross functional
representation with a core team having representatives from HS&E, Sourcing
and Logistics. The group will have responsibility of ensuring the actions detailed
in Section 3 are executed.
Based on project requirements, and on future requirements, it is likely the APC
group will have broader representation to ensure a comprehensive approach to
packaging review. The formation of a Packaging Review Group (PRG) across all
our manufacturing facilities has been identified as an action item included in our
2011-2015 action plan (Action Item 2, Section 3.1).
2.3. Implementation Process for SPG
The implementation of the SPG in accordance with the requirements of the APC
will be a phased approach to ensure a successful and integrated approach to
packaging review against the SPG.
As part of our 2011-2015 action plan development, packaging was categorised
into Primary, Secondary and Tertiary to identify key areas of focus (independent
of the outcome from action item #1) in meeting the requirements of the APC. 2
The process will be:
Establish team across both Manufacturing Sites.
Develop internal assessment guidelines for PRG integration.
Investigate feasibility of packaging evaluation tools to support the
goals of the APC (off the shelf).
Embed SPG considerations into current PRG process.
Assess Packaging based on classification (Primary, Secondary, and
Tertiary) and suppliers with initial focus on existing secondary and
tertiary packaging.
Review process adequacy for “future/new” packaging.
2 Process of reviewing existing packaging may be modified pending outcomes of evaluation tools used.
7

3. Action Plan
3.1. Design
Goal KPI Action Item Responsibility Timeframe
Performance
Measure
Additional
Commentary
1. Design: Optimise
packaging to achieve
resource efficiency
and reduce
environmental impact
without
compromising
product quality and
safety
1. Proportion of
signatories in the
supply chain
implementing the
Sustainable
Packaging
Guidelines for
design of
procurement of
packaging.
1. Review CSL’s product streams and
distribution processes to ascertain products
applicable to the Australian Packaging
Covenant.
2. Establish team to conduct reviews of
packaging for all facilities.
(Packaging Review Group)
Logistics Sep 2011 List of products and
distribution.
Separation of
“consumer” and
B2B.
Sourcing Dec 2011 PRG Minutes
PRG Charter
Required to determine
what we include /
exclude as part of
Australian Packaging
Covenant.
3. Develop internal guidelines, aligning to the
Sustainable Packaging Guidelines for review
during packaging review process
Sourcing, Logistics,
HS&E
Jul 2011
Guideline Template
4. Modify Packaging Review Group Approval
Form to include Sustainable Packaging
Guideline reference.
Sourcing / HS&E Jul 2011 Modified Form
5. Implement Sustainable Packaging Guidelines
for 50% of CSL’s existing products.
Investigate packaging evaluation tools to
support SPG integration and decision
making process.
Packaging Review
Group, Sourcing,
HS&E, Logistics
Tool
evaluation by
Jun 2011.
20% by 2013.
50% by 2015
Total packaging
items of 899
Target areas to be on
secondary and
tertiary items.
Primary Items: 67
Secondary items: 788
Tertiary Items: 44
Assessment process
may be modified
dependant on
evaluation tool
adopted.
6. Implement Sustainable Packaging Guidelines
for 100% of all new products by 2015.
(Post Action 1 to 4)
Packaging Review
Group, Sourcing,
HS&E, Logistics
2015 Demonstrated
review process.
8

3.2. Recycling
Goal KPI Action Item Responsibility Timeframe
2. Recycling: The
efficient collection
and recycling of
packaging.
2. National recycling
rate for packaging.*
3. Proportion of
signatories with onsite
recovery systems
for recycling used
packaging.
Not Applicable.
7. Investigate replacement of wooden pallets
within packaging with cardboard pallets.
8. Review packaging waste streams and identify
opportunities for reduction.
o Map waste streams
o Identify focus areas and
opportunities.
9. Monitor recycling rates for packaging and
performance at CSL facilities.
Performance
Measure
Logistics Dec 2011 Result of
Investigation
Emails
Meeting Minutes
Evidence of Use
(if applicable)
Sourcing / Logistics Jun 2012 List of packaging
waste streams and
disposal method.
HS&E
Annually by
October.
Metrics on recycling
rates for packaging.
Additional
Commentary
May be modified,
dependant on
Evaluation tools.
Technical
feasibility
4. Proportion of
signatories with a
policy to buy
products made from
recycled packaging.
5. Additional tonnes of
material reprocessed
in primary and
secondary markets as
a result of Covenantfunded
projects.*
10. Review CSL’s environmental policies to
include specific reference to packaging if
applicable.
Not Applicable.
Sourcing, HS&E Dec 2011 Result of review and
potential timeframe
for modification if
applicable – in line
with CSL’s
document review
process.
9

3.3. Product Stewardship
Goal KPI Action Item Responsibility Timeframe
3. Product
Stewardship: a
demonstrated
commitment to
product stewardship
by the supply chain
and other signatories.
6. Proportion of
signatories that have
formal processes for
working with others
to improve design
and recycling of
packaging.
7. Proportion of
signatories
demonstrating other
product stewardship
outcomes.
8. Reduction in the
number of packaging
items in the litter
stream.
11. Review of HS&E Management System
documents to reflect the requirements of
the Sustainable Packaging Guidelines:
RGL – 020: Procurement
RGL – 063: Management of Wastes
RGL – 065: Reuse and Recycling
RGL – 066: Waste Management
RGL – 121: Waste Disposal
12. Review inbound transport for improvement
opportunities.
13. Review packaging formats of raw/starting
materials to determine opportunities for
reduction.
Conduct initial feasibility review.
14. Conduct route analysis for CSL products to
determine environmental footprint and
assess opportunities for improvement.
15. Include environmental considerations in
tendering process.
Develop checklist/questionnaire
Include in tender documentation
Update Item Master Addition for
Purchased Items (HS&E Section).
16. Complete environmental audit of waste
contractor [3 yearly]
17. Investigate options for “Please Recycle”
cardboard logos on shippers and individual
cartons.
Performance
Measure
Additional
Commentary
HS&E Jun 2012 Updated Documents Consolidation of
documentation may
occur as a result of
Global HS&E
initiatives.
Logistics Jun 2013 Review report.
Emails
Minutes
Filenotes
Sourcing, Logistics Jun 2015 Outcome of
feasibility review to
examine merit for
progression.
Emails/Minutes
Summary
Filenotes
Logistics / HS&E Dec 2012 Route analysis
report.
Opportunities
and costs.
HS&E / Sourcing Jul 2011 Tender template
Tender
evidence.
HS&E Jun 2012 Audit Report
PRG Dec 2010
Complete
Roll out of
Please Recycled
logo on shippers
and individual
cartons.
10

3.4. Action Plan Endorsement
_______________________________
Jeff Davies
Executive Vice President
CSL Biotherapies
11